Project Grant F31CA301906
Award Date 12/1/26
Completion Date 6/30/29
Dollars Obligated $100K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary Rockefeller University received a $559,596 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award supports research to identify limiting mitochondrial metabolites that drive the initiation and progression of primary liver cancers, particularly hepatocellular carcinoma (HCC). The research leverages a proprietary organelle immunopurification technique...
- Federal Project Grant Award Summary Rockefeller University received a $100,228 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2026 through May 31, 2028. The award supports research and training focused on characterizing Multidrug Resistance Protein 1 (MRP1) and developing MRP1-specific inhibitors to overcome chemoresistance in cancer treatment. The project addresses a critical clinical challenge, as...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $501,422 Project Grant to Columbia University's Health Sciences Division, effective May 1, 2026 through April 30, 2031, under the Cancer Biology Research program (CFDA 93.396). The award funds fundamental research to identify and validate novel synthetic lethal (SL) targets for cancer treatment, specifically exploiting ribosomal stress in two molecularly distinct cancer subtypes: biallelic chromosome 9p21.3-deleted...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $182,755.00 to Cold Spring Harbor Laboratory through the Cancer Biology Research program (CFDA 93.396) to support research on genetic technology development for elucidating lineage plasticity mechanisms in cancer. The project, which commenced on August 21, 2025, and is scheduled for completion on July 31, 2030, will deliver advanced genetic screening technologies and methodologies designed to probe lineage identity...
- Federal Grant Award Summary Cold Spring Harbor Laboratory received a $704,182 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on June 16, 2026, with a completion date of May 31, 2031. The award funds fundamental research to elucidate the non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer (CRC). The research employs a novel mouse model that recapitulates the stepwise acquisition of...
- Federal Grant Award Summary The National Cancer Institute, under the Cancer Treatment Research program (CFDA 93.395), awarded The Trustees of Columbia University in the City of New York a $682,673 Project Grant effective May 1, 2026, through April 30, 2031. This award supports research investigating the development and mechanisms of resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma (PDAC). The research builds upon preclinical findings demonstrating that RMC-7977, a novel...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $630,089 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. This award funds research to characterize the molecular functions of SMARCAL1, a DNA translocase protein involved in regulating anti-tumor immune responses. The research addresses a critical gap in cancer immunotherapy by...